[go: up one dir, main page]

PE20191082A1 - Inhibidores de la tirosina quinasa de bruton - Google Patents

Inhibidores de la tirosina quinasa de bruton

Info

Publication number
PE20191082A1
PE20191082A1 PE2019001009A PE2019001009A PE20191082A1 PE 20191082 A1 PE20191082 A1 PE 20191082A1 PE 2019001009 A PE2019001009 A PE 2019001009A PE 2019001009 A PE2019001009 A PE 2019001009A PE 20191082 A1 PE20191082 A1 PE 20191082A1
Authority
PE
Peru
Prior art keywords
tyrosine kinase
kinase inhibitors
fragment
bruton tyrosine
hal
Prior art date
Application number
PE2019001009A
Other languages
English (en)
Inventor
Aleksey Sergeevich Gavrilov
Pavel Aleksandrovich Aleshunin
Svetlana Leonidovna Gorbunova
Mikhail Vladimirovich Rekharsky
Natalia Vladimirovna Kozhemyakina
Anna Aleksandrovna Kukushkina
Leonid Evgen'evich Mikhaylov
Alexander Moldavsky
Aleksandra Vladimirovna Popkova
Sergey Aleksandrovich Silonov
Svetlana Sergeevna Smirnova
Pavel Anadreevich Iakovlev
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of PE20191082A1 publication Critical patent/PE20191082A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a un compuesto de formula I, donde: V1 es C o N; V2 es C(R2) o N; n y k son 0 o 1; R2 y R11 son H, CN, entre otros; R3 es H, hidroxi, entre otros; R4 es H, alquilo C1-C6, entre otros; L es CH2, NH, entre otros; R1 es Fragmento 1, Fragmento 2 o Fragmento 3, donde A1, A2, A3 y A4 son CH, N o CHal; A5, A6, A7, A8 y A9 son C, CH o N; R5 es H, Hal, entre otros; R6 es a, b, c o d; R7, R8, R9 y R10 son vinilo o metilacetilenilo; y Hal es Cl, Br, I o F. Tambien se refiere a composiciones farmaceuticas que comprenden al compuesto. La presente invencion es util como inhibidor de la tirosina quinasa de Bruton (Btk) para el tratamiento de enfermedades tales como trastornos inmunitarios, cancer, trastornos alergicos, entre otras
PE2019001009A 2016-11-18 2017-11-16 Inhibidores de la tirosina quinasa de bruton PE20191082A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662424041P 2016-11-18 2016-11-18
PCT/IB2017/057154 WO2018092047A1 (en) 2016-11-18 2017-11-16 Inhibitors of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
PE20191082A1 true PE20191082A1 (es) 2019-08-20

Family

ID=60574666

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001009A PE20191082A1 (es) 2016-11-18 2017-11-16 Inhibidores de la tirosina quinasa de bruton

Country Status (19)

Country Link
US (1) US20190352276A1 (es)
EP (1) EP3541811A1 (es)
JP (1) JP2019537611A (es)
KR (1) KR20190104516A (es)
CN (1) CN110177781A (es)
AU (1) AU2017362066A1 (es)
BR (1) BR112019009945A2 (es)
CA (1) CA3043297A1 (es)
CL (1) CL2019001330A1 (es)
CR (1) CR20190261A (es)
EA (1) EA201990902A1 (es)
EC (1) ECSP19043231A (es)
JO (1) JOP20190113A1 (es)
MA (1) MA45888A1 (es)
MX (1) MX2019005706A (es)
PE (1) PE20191082A1 (es)
PH (1) PH12019550083A1 (es)
WO (1) WO2018092047A1 (es)
ZA (1) ZA201903694B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793566B2 (en) * 2016-01-21 2020-10-06 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
WO2019013562A1 (ko) * 2017-07-12 2019-01-17 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
KR102384924B1 (ko) * 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
EP3829543A1 (en) 2018-07-31 2021-06-09 Loxo Oncology, Inc. Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide
PL4036095T3 (pl) * 2019-09-26 2024-04-15 Jumbo Drug Bank Co., Ltd. Pochodne 4-fluoro-1H-pyrazolo[3,4-c]pirydyny jako selektywne inhibitory kinazy tyrozynowej Brutona (BTK) w leczeniu chłoniaka z komórek B i chorób autoimmunologicznych
CA3189912A1 (en) * 2020-08-17 2022-02-24 Xiaofeng Xu Bicyclic compounds, compositions and use thereof
CN114478519B (zh) * 2020-10-23 2024-06-11 励缔(杭州)医药科技有限公司 吡唑并吡啶类化合物或其盐及其制备方法和用途
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN116348453B (zh) * 2021-04-25 2025-07-04 烨辉医药科技(上海)有限公司 杂芳族甲酰胺化合物及其用途
WO2025202889A1 (en) * 2024-03-28 2025-10-02 Array Biopharma Inc. Her2 mutation inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681756C (en) * 2007-03-28 2015-02-24 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8846673B2 (en) * 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US20140045813A1 (en) * 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
WO2015095099A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
JP6162904B2 (ja) * 2014-02-03 2017-07-12 カディラ ヘルスケア リミティド 新規複素環式化合物
CN106999494A (zh) * 2014-08-01 2017-08-01 药品循环有限公司 布鲁顿酪氨酸激酶的抑制剂
MX384833B (es) * 2016-01-21 2025-03-14 Zibo Biopolar Changsheng Pharmaceutical Co Ltd Inhibidores de tirosina quinasa de bruton
WO2017156495A1 (en) * 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating bruton's tyrosine kinase

Also Published As

Publication number Publication date
CN110177781A (zh) 2019-08-27
CR20190261A (es) 2019-09-02
ZA201903694B (en) 2021-04-28
AU2017362066A1 (en) 2019-05-30
KR20190104516A (ko) 2019-09-10
JOP20190113A1 (ar) 2019-05-15
EP3541811A1 (en) 2019-09-25
US20190352276A1 (en) 2019-11-21
PH12019550083A1 (en) 2020-03-09
CL2019001330A1 (es) 2019-09-27
WO2018092047A1 (en) 2018-05-24
EA201990902A1 (ru) 2019-11-29
JP2019537611A (ja) 2019-12-26
MX2019005706A (es) 2019-07-08
CA3043297A1 (en) 2018-05-24
ECSP19043231A (es) 2019-06-30
BR112019009945A2 (pt) 2019-08-13
MA45888A1 (fr) 2020-06-30

Similar Documents

Publication Publication Date Title
PE20191082A1 (es) Inhibidores de la tirosina quinasa de bruton
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
DOP2020000037A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
AR116115A1 (es) Dimetil amino azetidina amidas como inhibidores de jak
AR109348A1 (es) Sulfonilureas y compuestos relacionados y sus usos
CL2020001343A1 (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
MY199446A (en) Compounds and compositions and uses thereof
DOP2015000289A (es) Compuestos de 3,4-dihidroisoquinolin-2(1h)-ilo
CY1123864T1 (el) Νεα παραγωγα αμινο-ιμιδαζοπυριδινης σαν αναστολεις κινασης janus και φαρμακευτικες χρησεις
SA521421262B1 (ar) مشتق أمين جديد حلقي غير متجانس وتركيبة صيدلانية تشتمل عليه
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
PE20221006A1 (es) Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae"
NZ746906A (en) Oxaborole esters and uses thereof
MX374426B (es) Sintesis de compuestos de triacetonadiamina mediante procedimiento de aminacion reductora de triacetonadiamina y derivados de los mismos.
CO2018007436A2 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
SA521422185B1 (ar) نظائر مُعالجة بالديوتيريوم للأسيتيل-ليوسين
PH12019500198A1 (en) Compounds and compositions and uses thereof